Amended Report of Foreign Issuer (6-k/a)
03 Fevereiro 2020 - 1:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February, 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
GSK publishes provisional dividend dates
The
following amendment has been made to the 'GSK publishes 2020
Dividend Dates' announcement released on 8 January 2020.
Q1
2020 Last date for DRIP elections amended to 18 June 2020.
All
other details remain unchanged.
The
full amended text is shown below.
|
Results
announcement
date
|
Ex-dividend
date
|
Record date
|
Last date for
DRIP elections
|
Payment date
|
Q1 2020
|
Wednesday
29
April
|
Thursday
14
May
|
Friday
15
May
|
Thursday
18
June
|
Thursday
9
July
|
Q2 2020
|
Wednesday
29
July
|
Thursday
13
August
|
Friday
14
August
|
Thursday
17
September
|
Thursday
8
October
|
Q3 2020
|
Wednesday
28
October
|
Thursday
12
November
|
Friday
13
November
|
Monday
21
December
|
Thursday
14
January 2021
|
Q4 2020
(Final)
|
Wednesday
3
February 2021
|
Thursday
18
February 2021
|
Friday
19
February 2021
|
Tuesday
16
March 2021
|
Thursday
8 April
2021
|
These
dates are indicative and may be subject to
change.
Victoria
Whyte
Company Secretary
3
February 2020
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
03, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (PK) (USOTC:GLAXF)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
GSK (PK) (USOTC:GLAXF)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre GSK Plc (PK) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Glaxosmithkline Plc